# NCT03941860 (NCT03941860)

> Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03941860
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Multiple Myeloma
- Interventions: Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Computed Tomography; Ixazomib Citrate; Lenalidomide; Placebo Administration; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 1
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03941860